



Tamiko Katsumoto

Clinical Associate Professor, Medicine - Immunology & Rheumatology

CLINICAL OFFICE (PRIMARY)

- **Immunology and Rheumatology Clinic**

900 Blake Wilbur Dr Rm W2081

2nd Fl

Stanford, CA 94305

Tel (650) 723-6961 Fax (650) 723-3059

Bio

BIO

Tamiko Katsumoto, MD, is a Clinical Associate Professor in the Division of Immunology and Rheumatology at Stanford University. She earned her MD from the University of California, San Francisco. She completed her internal medicine residency and rheumatology fellowship at UCSF, including a postdoc in immunology. Deeply committed to human and planetary health, she is passionate about educating her patients and colleagues on the merits of sustainable plant-rich diets as a strategy to both improve individual health and mitigate climate change and environmental degradation. She is fascinated by the impact of diet on inflammation and autoimmunity. She serves as the director of the Stanford Immune Related Toxicity Working Group, a multidisciplinary group which aims to improve the quality of care of cancer patients on immune checkpoint inhibitors. She has been investigating the impact of diet on immune-related adverse events. She is also intrigued by the relationship between cancer and autoimmune diseases, including diseases such as scleroderma and dermatomyositis, and the paraneoplastic manifestations of various cancers. She is involved in several clinical trials at Stanford and has spent time at Genentech, where she led several global clinical trials in immunology.

CLINICAL FOCUS

- Rheumatology
- Immunology
- Immuno-Oncology and immune-related adverse events
- Scleroderma (Systemic Sclerosis)

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Immunology & Rheumatology

HONORS AND AWARDS

- Innovations in Care Award, Stanford Health Care (2024)
- Jo Rae Wright Early Career Investigator Award, American Thoracic Society (2012)
- Laura Bechtel Junior Faculty Award, UCSF (2012)

- Rheumatology Investigator Award, American College of Rheumatology - Research and Education Foundation (2011-2013)
- Physician Scientist Development Award, American College of Rheumatology - Research and Education Foundation (2008-2011)
- Molecular Medicine Fellow, UCSF (2002-2008)
- Professionalism Award, UCSF Internal Medicine Residency Program (2005)
- Alpha Omega Alpha honor society, UCSF chapter (2002)
- Dean's Prize for Student Research, UCSF (2002)
- Research Fellowship and Support for Completion of Medical Studies, Howard Hughes Medical Institute (1999-2001)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American College of Rheumatology (2005 - present)
- Member, Society for Immunotherapy of Cancer (SITC) (2019 - present)
- Academic Working Group, Food Tank (2022 - present)
- Co-chair, ACR Climate Change Task Force (2024 - present)
- Co-chair, Arthritis Foundation Medical and Scientific Board (2024 - present)

PROFESSIONAL EDUCATION

- Board Certification: Rheumatology, American Board of Internal Medicine (2008)
- Fellowship: UCSF Rheumatology Fellowship (2008) CA
- Residency: UCSF Department of Medicine (2005) CA
- Medical Education: University of California at San Francisco School of Medicine (2002) CA

Research & Scholarship

CLINICAL TRIALS

- The Stanford Plant-based Educational Study: Providers Learning About Nutrition Together (PLANT), Not Recruiting

Publications

PUBLICATIONS

- **Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: a systematic literature review and meta-analysis.** *Frontiers in immunology*
Strouse, J., Chan, K. K., Baccile, R., He, G., Loudon, D. K., Giurcanu, M., Singh, A., Rieth, J., Abdel-Wahab, N., Katsumoto, T. R., Singh, N., Rouhani, S., Reid, et al
2024; 15: 1499478
- **Assessing the Feasibility of a Mediterranean-Style Diet for Patients with Rheumatoid Arthritis in a Racially and Culturally Diverse Population Across the United States**
Thompson, C., Ventura, I., Edens, C., Katsumoto, T., Popuri, S.
WILEY.2024: 3411-3413
- **Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis.** *Rheumatic diseases clinics of North America*
Gomez-Puerta, J. A., Gente, K., Katsumoto, T. R., Leipe, J., Reid, P., van Binsbergen, W. H., Suarez-Almazor, M. E.
2024; 50 (2): 161-179
- **Aromatase inhibitor-induced arthralgia ameliorated by Mediterranean diet and active lifestyle guided by continuous glucose monitoring: a case report and review of the literature.** *Frontiers in oncology*
Wilson, K. L., Grewelle, R. E., Gupta, T., Kim, S. H., Katsumoto, T. R.
2024; 14: 1189287
- **Impact of climate change on rheumatic diseases: A scoping review** *The Journal of Climate Change and Health*

Katsumoto, T. R., Stolyar, L., Dandeniya, C. L., Wong, H. N., Lanata, C. M., Falasinnu, T., Bush, T.
2024

- **Plasma Exchange in Patients With Myositis due to Immune Checkpoint Inhibitor Therapy.** *Journal of clinical neuromuscular disease*
Katyal, N., Katsumoto, T. R., Ramachandran, K. J., Yunce, M., Muppidi, S.
2023; 25 (2): 89-93
- **A CASE REPORT OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) ASSOCIATED WITH ANTI-PD-1 IMMUNE CHECKPOINT INHIBITOR (ICI) THERAPY WITH CEMIPIMAB AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) : ATTEMPTING DRUG REMOVAL WITH PLASMA EXCHANGE (PLEX) IS NOT SUFFICIENT**
Martin-Kool, B., Katsumoto, T., Giri, V.
WILEY.2023: S31
- **Plasma Exchange for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Therapy: Implications for Clinical Care and Clinical Trial Design**
Giri, V. K., Yunce, M., Muppidi, S., Ramchandran, K. J., Katsumoto, T. R., Martin-Kool, B. A.
AMER SOC HEMATOLOGY.2022: 2835-2836
- **U.S. medical organizations and climate change advocacy: a review of public facing websites.** *BMC public health*
Bush, T., Jensen, W. A., Katsumoto, T. R.
2022; 22 (1): 1950
- **Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?** *Immunotherapy advances*
Katsumoto, T. R., Wilson, K. L., Giri, V. K., Zhu, H., Anand, S., Ramchandran, K. J., Martin, B. A., Yunce, M., Muppidi, S.
2022; 2 (1): Itac012
- **A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).**
Dumbrava, E., Dougan, M. L., Gupta, S., Cappelli, L., Katsumoto, T. R., Rahma, O. E., Painter, J., Wang, Y., Suarez-Almazor, M. E., Reid, P., Wesley, S. F., Hafler, D. A., Bingham, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Immune Checkpoint Inhibitor Pneumonitis: Heterogeneity in Clinical Management**
Filsoof, D., Padda, S. K., Garcia, P., Stedman, M., Neal, J. W., Wakelee, H. A., Ramchandran, K., Das, M., Ramsey, M., Bedi, H. S., Sung, A., Raj, R., Anand, et al
AMER THORACIC SOC.2021
- **Pragmatic Application of Computed Tomography Lung Texture Analysis in Immune Checkpoint Inhibitor Pneumonitis: An Exploratory Study**
Filsoof, D., Im, J., Garcia, P., Stedman, M., Anand, S., Neal, J. W., Wakelee, H. A., Ramchandran, K., Das, M., Padda, S. K., Sharifi, H., Mooney, J. J., Tsai, et al
AMER THORACIC SOC.2021
- **A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).**
Dumbrava, E., Suarez-Almazor, M. E., Painter, J., Johanns, T., Dougan, M. L., Cappelli, L., Bingham, C. O., Wang, Y., Gupta, S., Warner, B. M., Rahma, O. E., Naidoo, J., Ott, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study).** *Arthritis & rheumatology (Hoboken, N.J.)*
Cohen, S., Tuckwell, K., Katsumoto, T. R., Zhao, R., Galanter, J., Lee, C., Rae, J., Toth, B., Ramamoorthi, N., Hackney, J. A., Berman, A., Damjanov, N., Fedkov, et al
2020
- **Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study**
Cohen, S., Tuckwell, K., Kunder, R., Katsumoto, T., Zhao, R., Berman, A., Damjanov, N., Fedkov, D., Jeka, S., Genovese, M.
WILEY.2019
- **Absence of Pharmacokinetic Interactions Between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate.** *The Journal of pharmacology and experimental therapeutics*
Jones, N. S., Winter, H., Katsumoto, T. R., Florero, M., Murray, E., Walker, H., Singh, N., Chinn, L.

2019

- **FENEBRUTINIB COMPARED TO PLACEBO AND ADALIMUMAB IN PATIENTS WITH INADEQUATE RESPONSE TO EITHER METHOTREXATE THERAPY OR PRIOR TNF THERAPY: PHASE 2 STUDY**
Cohen, S., Tuckwell, K., Katsumoto, T. R., Zhao, R., Lee, C., Berman, A., Damjanov, N., Fedkov, D., Jeka, S., Genovese, M. C.
BMJ PUBLISHING GROUP.2019: 80–81
- **Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis.** *Lupus science & medicine*
Gomez Mendez, L. M., Cascino, M. D., Katsumoto, T. R., Brakeman, P., Brunetta, P., Jayne, D., Dall'Era, M., Rovin, B., Garg, J.
2019; 6 (1): e000308
- **Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies.** *Current treatment options in oncology*
Lippner, E. A., Lewis, D. B., Robinson, W. H., Katsumoto, T. R.
2019; 20 (7): 62
- **Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.** *Clinical journal of the American Society of Nephrology : CJASN*
Gomez Mendez, L. M., Cascino, M. D., Garg, J., Katsumoto, T. R., Brakeman, P., Dall'Era, M., Looney, R. J., Rovin, B., Dragone, L., Brunetta, P.
2018; 13 (10): 1502-1509
- **Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.** *Clinical pharmacology and therapeutics*
Herman, A. E., Chinn, L. W., Kotwal, S. G., Murray, E. R., Zhao, R., Florero, M., Lin, A., Moein, A., Wang, R., Bremer, M., Kokubu, S., Serone, A. P., Hanze, et al
2018; 103 (6): 1020-1028
- **Brief Report: Whole-Exome Sequencing for Identification of Potential Causal Variants for Diffuse Cutaneous Systemic Sclerosis.** *Arthritis & rheumatology (Hoboken, N.J.)*
Mak, A. C., Tang, P. L., Cleveland, C., Smith, M. H., Kari Connolly, M., Katsumoto, T. R., Wolters, P. J., Kwok, P. Y., Criswell, L. A.
2016; 68 (9): 2257-62
- **The phosphatase CD148 promotes airway hyperresponsiveness through SRC family kinases.** *The Journal of clinical investigation*
Katsumoto, T. R., Kudo, M., Chen, C., Sundaram, A., Callahan, E. C., Zhu, J. W., Lin, J., Rosen, C. E., Manz, B. N., Lee, J. W., Matthey, M. A., Huang, X., Sheppard, et al
2013; 123 (5): 2037-48
- **Outcomes in systemic sclerosis-related lung disease after lung transplantation.** *Transplantation*
Sottile, P. D., Iturbe, D., Katsumoto, T. R., Connolly, M. K., Collard, H. R., Leard, L. A., Hays, S., Golden, J. A., Hoopes, C., Kukreja, J., Singer, J. P.
2013; 95 (7): 975-80
- **Cut to the quick.** *Journal of hospital medicine*
Su, R., Katsumoto, T. R., George, V., Gundling, K., Hollander, H.
2013; 8 (2): 110-3
- **Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.** *Respiratory medicine*
Lee, J. S., Kim, E. J., Lynch, K. L., Elicker, B., Ryerson, C. J., Katsumoto, T. R., Shum, A. K., Wolters, P. J., Cerri, S., Richeldi, L., Jones, K. D., King, T. E., Collard, et al
2013; 107 (2): 249-55
- **Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts.** *Seminars in arthritis and rheumatism*
Walker, K. M., Pope, J.
2012; 42 (1): 42-55
- **The pathogenesis of systemic sclerosis.** *Annual review of pathology*
Katsumoto, T. R., Whitfield, M. L., Connolly, M. K.
2011; 6: 509-37
- **Blocking TGF β via Inhibition of the α v β 6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease.** *International journal of rheumatology*
Katsumoto, T. R., Violette, S. M., Sheppard, D.

2011; 2011: 208219

- **Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis.** *The Journal of rheumatology*
Walker, K. M., Pope, J.
2011; 38 (7): 1326-8
- **Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'.** *Nature*
Goodridge, H. S., Reyes, C. N., Becker, C. A., Katsumoto, T. R., Ma, J., Wolf, A. J., Bose, N., Chan, A. S., Magee, A. S., Danielson, M. E., Weiss, A., Vasilakos, J. P., Underhill, et al
2011; 472 (7344): 471-5
- **Structurally distinct phosphatases CD45 and CD148 both regulate B cell and macrophage immunoreceptor signaling.** *Immunity*
Zhu, J. W., Brdicka, T., Katsumoto, T. R., Lin, J., Weiss, A.
2008; 28 (2): 183-96
- **Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells.** *The Journal of experimental medicine*
Katsumoto, T. R., Duda, J., Kim, A., Wardak, Z., Dranoff, G., Clapp, D. W., Shannon, K.
2005; 201 (6): 853-8
- **Polymerized liposome assemblies: Bifunctional macromolecular selectin inhibitors mimicking physiological selectin ligands** *BIOCHEMISTRY*
Bruehl, R. E., Dasgupta, F., Katsumoto, T. R., Tan, J. H., Bertozzi, C. R., Spevak, W., Ahn, D. J., ROSEN, S. D., Nagy, J. O.
2001; 40 (20): 5964-5974
- **Ligation of L-selectin on T lymphocytes activates beta1 integrins and promotes adhesion to fibronectin.** *Journal of immunology (Baltimore, Md. : 1950)*
Giblin, P. A., Hwang, S. T., Katsumoto, T. R., Rosen, S. D.
1997; 159 (7): 3498-507
- **L-selectin-carbohydrate interactions: Relevant modifications of the Lewis x trisaccharide** *BIOCHEMISTRY*
Sanders, W. J., Katsumoto, T. R., Bertozzi, C. R., ROSEN, S. D., Kiessling, L. L.
1996; 35 (47): 14862-14867